Michael Shawn Moran - 28 Feb 2022 Form 4 Insider Report for EAGLE PHARMACEUTICALS, INC. (EGRX)

Reporting relationship: EVP, Chief Commercial Officer
Issuer ticker: EGRX
Reported as of: 28 Feb 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Mar 2022, 17:11:09 UTC
Prior SEC filing: 04 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/ Brian Cahill, Attorney-in-Fact

Key filing fact

Michael Shawn Moran filed Form 4 for EAGLE PHARMACEUTICALS, INC. (EGRX) on 02 Mar 2022.

Key facts

This page summarizes Michael Shawn Moran's Form 4 filing for EAGLE PHARMACEUTICALS, INC. (EGRX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Mar 2022, 17:11.

Change

Previous filing in this sequence was filed on 04 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EGRX transaction

Common Stock

Award

Transaction value: $0
Shares: +10,400
Change %: +48%
Price: $0.000000
Shares after: 32,115
Date: 28 Feb 2022
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock upon vesting of the unit. The shares issuable in respect of such RSUs shall vest with respect to 25% of the shares of common stock on each of the one, two, three and four-year anniversaries of February 28, 2022, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.